Remdesivir against COVID-19 and Other Viral Diseases-Reference-Cited by-同舟云学术

Remdesivir against COVID-19 and Other Viral Diseases

Published:2020-12-16 Issue:1 Volume:34 Page:
ISSN:0893-8512
Container-title:Clinical Microbiology Reviews
language:en
Short-container-title:Clin Microbiol Rev

Author:

Malin Jakob J.¹²^ORCID,Suárez Isabelle¹³,Priesner Vanessa¹,Fätkenheuer Gerd¹,Rybniker Jan¹²³

Affiliation:

1. Department I of Internal Medicine, Division of Infectious Diseases, University of Cologne, Cologne, Germany

2. Faculty of Medicine, Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany

3. German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany

Abstract

Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic. Remdesivir (GS-5734) is the first approved treatment for severe coronavirus disease 2019 (COVID-19). It is a novel nucleoside analog with a broad antiviral activity spectrum among RNA viruses, including ebolavirus (EBOV) and the respiratory pathogens Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology

Link

https://journals.asm.org/doi/pdf/10.1128/CMR.00162-20

Reference77 articles.

1. Coronavirus Disease 2019–COVID-19

2. Johns Hopkins University. 2020. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE). Johns Hopkins University, Baltimore, MD. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. Accessed 6 July 2020.

3. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

4. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

5. Remdesivir for the Treatment of Covid-19 — Final Report

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential therapeutic landscape of COVID-19: molecular targets, repurposed drugs, and nano- and cell-based intervention;Stem Cells;2024

2. CHITV: an updated combination treatment regimen for COVID-19;Molecular Medical Microbiology;2024

3. COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2;Molecular Medical Microbiology;2024

4. Introductory Chapter: Current Landscape of Animal and Human Virus Treatments;Infectious Diseases;2023-12-20

5. Is antiviral treatment at the acute phase of COVID-19 effective for decreasing the risk of long-COVID? A systematic review;Infection;2023-12-19